H
Hartmut Doehner
Researcher at University of Ulm
Publications - 38
Citations - 3013
Hartmut Doehner is an academic researcher from University of Ulm. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 11, co-authored 38 publications receiving 2841 citations. Previous affiliations of Hartmut Doehner include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson,John M. Bennett,Kenneth J. Kopecky,Thomas Büchner,Cheryl L. Willman,Elihu H. Estey,Charles A. Schiffer,Hartmut Doehner,Martin S. Tallman,T. Andrew Lister,Francesco Lo-Coco,Roel Willemze,Andrea Biondi,Wolfgang Hiddemann,Richard A. Larson,Bob Löwenberg,Miguel A. Sanz,David R. Head,Ryuzo Ohno,Clara D. Bloomfield +19 more
TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.
Journal Article
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,515 cases of AML
S Groeschel,Sanne Lugthart,Berna Beverloo,Sabine Kayser,Peter J. M. Valk,S. L Van Zelderen-Bhola,G-J Ossenkoppele,Edo Vellenga,E van den Berg-de Ruiter,Urs Schanz,Gregor Verhoef,Augustin Ferrant,C-H Koehne,Michael Pfreundschuh,H-A Horst,Elisabeth Koller,M. von Lilienfeld-Toal,Martin Bentz,Arnold Ganser,Brigitte Schlegelberger,Martine Jotterand,Jürgen Krauter,Thomas Pabst,Matthias Theobald,Richard F. Schlenk,Ruud Delwel,Konstanze Doehner,Bob Löwenberg,Hartmut Doehner +28 more
TL;DR: Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features.
Journal ArticleDOI
First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.
Michael Hallek,Guenter Fingerle-Rowson,Anna-Maria Fink,Raymonde Busch,Jiri Mayer,Manfred Hensel,Georg Hopfinger,Georg Hess,Ulrich von Gruenhagen,Manuela Bergmann,John Catalano,Pier Luigi Zinzano,Federico Caligaris Cappio,John F. Seymour,Alain Berrebi,Ulrich Jaeger,Bruno Cazin,Marek Trneny,Anne Westermann,Clemens-Martin Wendtner,Barbara Eichhorst,Peter Staib,Sebastian Boettcher,Matthias Ritgen,Myriam Mendila,Michael Kneba,Hartmut Doehner,Stephan Stilgenbauer,Kirsten Fischer +28 more
TL;DR: Hallek et al. as mentioned in this paper reported the first results of a multicenter, international randomized phase III trial (CLL8) showing superiority of FCR chemoimmunotherapy for response rates and progression-free survival when compared to FC chemotherapy.
Journal ArticleDOI
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia.
Maria Teresa Voso,Stefan Hohaus,Francesco Guidi,Emiliano Fabiani,Francesco D'Alo',S Groner,D Späth,Konstanze Doehner,Giuseppe Leone,Hartmut Doehner,Richard F. Schlenk +10 more
TL;DR: The prognostic role of polymorphisms in three GST genes (GSTP1/M1/T1) in a large patient cohort of the German Austrian Acute Myeloid Leukemia Study Group is studied, finding the favorable impact of GSTP1*105 Val on RFS seems to be restricted to the subgroup of patients exhibiting a normal karyotype.
Journal ArticleDOI
Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy.
TL;DR: Two patients with idiopathic hypereosinophilic syndrome refractory to treatment with corticosteroids and hydroxyurea received alpha-interferon (alpha-IFN) for 3 and 1 years, respectively, and more than a year after discontinuation, 1 patient remains in a stable remission.